Introduction {#Sec1}
============

Understanding the epidemiology and timing of respiratory virus infections (RVI) after allogeneic hematopoietic stem cell transplantation (allo-HCT) is important for appropriate preventive strategies, effective diagnosis, accurate risk assessment of severe disease course, and/or treatment decision making in individual patients. The epidemiology of community acquired respiratory virus (CARV) infections among allo-HCT closely parallels incidence of infection in the community \[[@CR1]\], although in immunocompromised patients these infections are notable for prolonged viral shedding, higher rates of pneumonia, late airflow obstruction, and mortality \[[@CR2], [@CR3]\].

Established and validated risk factors for progression from upper respiratory tract disease (URTD) to lower respiratory tract disease (LRTD) and mortality include recipient age, smoking history, high APACHE II score, lymphopenia, high-dose total body irradiation, high-dose steroids, and presence of copathogens \[[@CR4]--[@CR8]\]. Validated risk scores have recently been proposed to predict respiratory syncytial virus (RSV) and influenza virus infections with greater accuracy \[[@CR1], [@CR9]--[@CR13]\]. Despite the suspicion in real life practice that the timing of CARV infection after allo-HCT could be related to increased severity and mortality, there is a lack of strong evidence supporting this belief. Although current risk scores include timing of CARV infection relative to timing of allo-HCT, the cut-off time points vary between different studies. Immunosuppression status in allo-HCT has classically been divided into preengraftment (up to neutrophil recovery), early postengraftment (from engraftment until day + 100), and late postengraftment (after day + 100). Based on this classification, several studies have analyzed the impact of timing on severity and mortality in different CARV type scenarios, with inconsistent results. Most studies used the aforementioned cut-off time points of 30 days and/or 100 days and/or 6 months and/or 1 year after stem cell infusion for comparison. Accordingly, some studies found that developing a CARV infection within 30 days after transplant was linked to worse outcome \[[@CR6], [@CR10]\] whereas others did not \[[@CR14]--[@CR18]\]. In addition, studies using day + 100 as a cut-off time could not show significant association with outcome \[[@CR19]--[@CR22]\], while others observed worse outcome for CARV infections occurring before day + 180 \[[@CR11]\]. Finally, while some studies found that CARVs beyond 1 year after allo-HCT showed favorable outcomes \[[@CR23]\], others did not \[[@CR14], [@CR17], [@CR24]\]. In summary, most studies found no effect on patient outcomes regarding the timing of CARV infection development, but due to the discordant results, this issue remains unresolved and warrants further research.

Herein, we evaluate the effect of timing of CARV infection on mortality in a consecutive series of allo-HCT recipients with molecularly-documented CARV infections during the first year after stem cell infusion.

Patients and methods {#Sec2}
====================

Study population and respiratory virus survey protocol {#Sec3}
------------------------------------------------------

This was a prospective observational longitudinal epidemiologic study of CARV infections in adult (\>18 years) allo-HCT recipients conducted at two Spanish transplant centers in Valencia, Spain. The cohort was comprised entirely of consecutive allo-HCT recipients with molecularly-documented CARV infections who were prospectively screened for respiratory viruses at the Hospital Clinic Universitari of Valencia (HCUV) between December 2013 and May 2016, and at the Hospital Universitari i Politècnic La Fe in Valencia (HLF) from June 2016 to December 2018.

The CARV survey methodology has previously been described in detail elsewhere \[[@CR1], [@CR25]\]. Briefly, from December 2013 at the HCUV and from May 2016 at the HLF, all consecutive patients with URTD and/or LRTD symptoms were encouraged to undergo detailed respiratory virus screening through molecular testing. We prospectively recorded clinical and biological characteristics at the time of CARV screening, including transplant characteristics, variables included in the immunodeficiency scoring index (ISI) \[[@CR9]\], hospital admission, immunosuppressant drugs, and signs or symptoms of acute or chronic GvHD. The local ethics committee approved the study protocol.

Standard of care for infection control practices and management of CARV infections {#Sec4}
----------------------------------------------------------------------------------

In December 2013 at the HCUV and in May 2016 at the HLF, we implemented the medical information/education for recipients and caregivers explaining in detail about the risks of having RVI in the context of immunosuppression. Specific information included a description of respiratory symptoms that merits urgent notification to the transplant team and recommendations concerning screening of respiratory virus, available therapies, and infectious prevention control measures for patients and health caregivers. Appropriate precautions and infection control measures for preventing CARV transmission in allo-HCT recipients with respiratory symptoms were instituted at both centers according to published guidelines \[[@CR26]\].

As per protocol, we started oseltamivir in allo-HCT recipients with influenza infection provided the respiratory symptoms have not been resolved at the time of microbiological results. Annual influenza vaccination was also recommended to all patients at both transplant centers after the 3rd month following allo-HCT. For patients with moderate to severe GVHD at the time of vaccination program who had received gammaglobulin, antithymocytic globuline (ATG) or rituximab within the 3 months before the flu vaccine period, vaccine administration remained at physician discretion \[[@CR1]\]. RSV and human parainfluenza virus (HPIV) were managed according to our interventional protocol \[[@CR27]\]. Briefly, oral ribavirin was given at a loading dose (maximum daily dose of 30 mg/kg) until resolution of respiratory symptoms. Routine prophylactic intravenous immunoglobulins (0.4 g/kg) were given when IgG serum levels were below 300 mg/dl. Ribavirin therapy was instituted in recipients with LRTD caused by RSV or HPIV, whereas patients with URTD must had 3 or more ISI points and/or 2 or more risk factor according to the ECIL-4 guidelines \[[@CR28]\], and/or presenting one or more coinfective virus(es) before starting ribavirin.

Cohort selection {#Sec5}
----------------

The current study analyzed all consecutive molecularly-proven CARV infectious episodes occurring during the first year after allo-HCT. The recipients/CARV episodes included were relapse-free of baseline disease before the CARV infection diagnosis. The study was conducted from December 1 2013 until December 26 2018. CARV related complication and survival status were updated on April 28 2019. We counted CARV episodes as follows: in recipients with more than one CARV infectious episode, we censored the episode at the time point of the following CARV episode diagnosis. For recipients who died after developing more than one CARV episode we counted the closest CARV episode for mortality, while the previous ones were censored as alive at the time of the following CARV episode.

Definitions {#Sec6}
-----------

URTD was defined as a combination of upper respiratory symptoms (rhinorrhea, sinusitis, otitis, or pharyngitis) as well as positive CARV diagnosis by PCR test in respiratory samples, and absence of LRTD symptoms and/or any indication of pulmonary infiltrates in chest X-ray or CT scan radiology results. We classified LRTD as possible, probable or confirmed, as previously described \[[@CR17]\]. There were no probable episodes because bronchoscopies were not performed in patients without radiological proof of pulmonary involvement. Respiratory virus infection episodes were defined according to ECIL-4 recommendations \[[@CR28]\].

Technical and diagnostic considerations {#Sec7}
---------------------------------------

CARV testing was performed with three RT-PCR multiplex platforms described in detail elsewhere \[[@CR1], [@CR25]\]. At the HCUV samples were tested by RT-PCR using the Luminex xTAG RVP Fast v1 assay (Luminex Molecular Diagnostics, Toronto, ON, Canada), while at HLF the CLART^®^ PneumoVir DNA array assay (Genomica, Coslada, Spain) was performed and interpreted during the study period following the manufacturer's recommendations. The Luminex xTAG RVP Fast v1 assay can detect adenoviruses (ADVs); human bocavirus (HBoV); human coronavirus (CoV) types 229E, HKU1, NL63, and OC43; influenza A virus A/H1N1, A/H3N2, and other influenza viruses (non-subtypificable); influenza B virus; human metapneumovirus (HMPV) A and B; HPIV 1, 2, 3, and 4A-4B; RSV A-B; and enterovirus/rhinovirus (EvRh). The CLART^®^ PneumoVir DNA array assay differs from the Luminex xTAG RVP Fast assay in that it detects influenza C virus but does not allow the detection of the alphacoronavirus NL63 virus and the betacoronaviruses HKU1 and OC43. The CLART^®^ PneumoVir is able to discriminate between rhinovirus and enterovirus genus, and it permits the identification of the new influenza A/H1N1v. At HLF from July 2018 onwards CARV screening in allo-HCT recipients was performed by BioFire FilmArray^®^ Respiratory Panel (BioFire Diagnostics (a bioMerieux company), Salt Lake City, UT), which is able to detect 15 respiratory viruses: influenza virus types A, B, and C (with influenza A subtyping), ADV, HCoV HKU1, NL63, 229E and OC43, HMPV, EvRh, HPIV types 1--4 and RSV, and also detects three bacteria: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Bordetella pertussis.

Endpoints and statistical analysis {#Sec8}
----------------------------------

The primary objective of the study was to assess 3-month all-cause mortality from time of CARV diagnosis according to the timing of CARV infection during the first year after allo-HCT. Secondary endpoints included identifying other risk factors for all-cause mortality and overall survival (OS).

Frequencies were compared using the *χ*^2^ test (Fisher exact test) for categorical variables. Differences between medians were compared using the Mann--Whitney *U* test. Univariate and multivariate analyses of how clinical and biological variables associated with 3-month all-cause mortality were calculated using logistic regression models. For multivariate analysis, only variables with parameter estimates showing a *P* value ≤ 0.10 in the univariate analysis were finally included. Two-sided exact *P* values were reported and *P* values ≤ 0.05 were considered statistically significant. The probability of OS according to the timing of CARV infection was estimated from the time of CARV detection using Kaplan--Meier curves \[[@CR29]\] and univariate comparisons were made with the log-rank test \[[@CR30]\]. The data was analyzed with the SPSS (version 20.0) statistical package.

Results {#Sec9}
=======

Overall, 326 allo-HCT recipients developed 804 episodes of upper and/or lower respiratory symptoms which were screened for CARVs. Among them, 298 allo-HCT recipients (91%) developed at least one episode of molecularly documented CARV, accounting for 633 CARV infection episodes (78%) during the six-year study period. After excluding 36 episodes (6%) that had occurred after baseline disease relapse, overall we considered 287 allo-HCT recipients with 597 consecutive molecularly-documented CARV infectious episodes. For study purposes, we excluded 221 CARV episodes occurring after the first year of transplant, including 54 allo-HCT recipients who developed their first CARV infection episode beyond the first year of transplant. Finally, we included 233 allo-HCT recipients who had developed 376 molecularly documented CARV infections during the first year after allo-HCT.

Clinical and transplant characteristics of the series are detailed in Table [1](#Tab1){ref-type="table"}. The study population comprised a high-risk cohort, since 70% of the recipients were allografted from alternative donors \[adult unrelated donor (URD), single cord blood units, or haplo-identical family donors\]. Human leukocyte antigen (HLA)-mismatch between donor and recipient (considering high resolution typing of HLA A, B, C, DRB1, and DQB1) represented 47% of the cohort. Sixty-one recipients (26%) received ATG because of URD-recipient HLA mismatch (*n* = 8), cord blood transplant (*n* = 47), or HLA-identical sibling in the context of a clinical trial (*n* = 6).Table 1Patient characteristicsCharacteristics(*n* = 233)Age (years), median (range)47 (18--70)Male, *n* (%)130 (56)Baseline disease, *n* (%)AL/MDS/MPD123 (53)/16 (7)/15 (6)Lymphoid disorders75 (32)Others4 (2)Disease status at transplant, *n* (%)CR161 (69)PR32 (14)Refractory/active disease40 (17)Prior ASCT, *n* (%)57 (25)Period of transplant, *n* (%)2017--201886 (37)2015--201662 (27)2013--201463 (27)201222 (9)Conditioning regimen, *n* (%)RIC105 (45)Type of donor, *n* (%)HLA-identical sibling donor70 (30)Unrelated donor59 (25)Umbilical cord blood51 (22)Haploidentical family donor53 (23)PB stem cell source, *n* (%175 (75)HLA fully-matched, *n* (%)123 (53)ATG as a part of conditioning regimen, *n* (%)61 (26)GvHD prophylaxis, *n* (%)Sir-Tac24 (10)CsA + MTX43 (18)Post-Cy106 (46)CsA + PDN and others60 (26)Number CARVs episodes by days after SC infusion, *n* (%)376Day −7 until Day +3063 (17)Day +31 to Day +6028 (7)Day  +61 to Day +9039 (10)Day  +91 to Day +18096 (26)Day +181 to Day +356150 (40)Number of LRTD CARV episodes140Median time from allo-HSCT to CARV, days (range)139 (−7 to 353)Median F/U after CARV, days (range)275 (0--2356)*AL* acute leukemia, *MDS* myelodysplastic syndrome, *MPD* myeloproliferative disease, *CR* complete remission, *PR* partial remission, *ASCT* autologous stem cell transplantation, *RIC* reduced intensity conditioning, *ATG* anti-thymocyte globuline, *Sir* sirolimus, *Tac* tacrolimus, *CsA* cyclosporine A, *MTX* methotrexate, *Post*-*Cy* posttransplant cyclophosphamide, *PDN* prednisone, *SC* stem cell, *allo*-*HSCT* allogeneic hematopoietic stem cell transplantation, *CARV* community-acquired respiratory virus, *F*/*U* follow-up, *IFD* invasive pulmonary infectious fungal disease, *LRTD* lower respiratory tract disease

CARV respiratory virus infection characteristics {#Sec10}
------------------------------------------------

CARV episodes were diagnosed at a median of 139 days after stem cell infusion (range, day −7 to +353). Two-hundred and thirty-six CARV episodes (63%) were limited to the URTD whereas 140 (37%) had LRTD involvement (72 possible LRTD and 68 proven LRTD). Table [2](#Tab2){ref-type="table"} summarizes the most common CARV types isolated, and the corresponding rates of URTD and LRTD.Table 2Type of CARV and mortality by CARV type and timing of respiratory virus infection and CARV upper or lower respiratory tract diseaseEvRhRSVInfluHPiVhMPVAdVHCoVHBoVNumber of episodes, *n* (%)^a^145 (39)100 (27)58 (15)65 (17)38 (10)8 (2)24 (6)10 (3)90-day overall mortality, *n* (%)^a^10 (7)12 (12)3 (5)5 (8)3 (8)1 (13)2 (8)0CARV URTD, *n* (%)^a^102 (70)54 (54)38 (65)37 (72)21 (55)2 (25)18 (75)9 (90)90-day overall mortality, *n* (%)^a^3 (3)2 (4)1 (3)2 (5)1 (5)01 (6)0CARV URTD from day −7 until day +180, *n*^a^64 (63)30 (56)18 (47)22 (59)14 (67)1 (50)10 (56)5 (56)90-day overall mortality, *n*^a^3 (5)2 (7)1 (5)1 (4)1 (7)01 (10)0CARV URTD from day +181 until 1 year, *n*^a^38 (37)24 (44)20 (53)15 (41)7 (33)1 (50)8 (44)4 (44)90-day overall mortality, *n* (%)^a^0001 (7)0000CARV LRTD, *n* (%)^a^43 (30)46 (46)20 (35)18 (28)17 (45)6 (75)6 (25)1 (10)90-day overall mortality, *n* (%)^a^7 (16)10 (22)2 (10)3 (17)2 (12)1 (17)1 (17)0CARV LRTD from day −7 until day +180, *n*^a^29 (67)29 (63)14 (70)13 (72)13 (76)4 (67)3 (50)1 (100)90-day overall mortality, *n* (%)^a^5 (17)9 (31)2 (14)2 (15)2 (15)1 (25)1 (33)0CARV LRTD from day +181 until 1 year, *n*^a^14 (33)17 (37)6 (30)5 (28)4 (24)2 (33)3 (50)090-day overall mortality, *n* (%)^a^2 (14)1 (6)01 (20)0000*CARV* community-acquired respiratory virus, *EvRh* enterovirus/rhinovirus, *ADV* adenovirus, *RSV* respiratory syncytial virus, *HPiV* human parainfluenza virus, *hMPV* human metapneumovirus, *HCoV* human coronavirus, *Influ* human influenza virus, *AdV* adenovirus, *IFD* invasive pulmonary fungal disease, *URTD* upper respiratory tract disease, *LRTD* lower respiratory tract disease^a^The sum total of the episodes does not match the overall number of episodes (*n* = 376) since multiple CARVs were detected in the same respiratory sample in 72 (19%) CARV episodes. 90-day all-cause mortality after CARV coviral infection was 8% (6 out of 72). Forty-one covirus infectious episodes occurred within the first 6 months after stem cell infusion and mortality was 15% (6 out of 41). Two (5%) out of 44 with URTD and four (14%) out of 28 patients with LRTD CARV coviral infection died. Finally, 4 (24%) out of 17 patients with LRTD CARV coviral infection occurring within the first 6 months after stem cell infusion died

CARV infection episode characteristics and 3-month all-cause mortality according to time of transplantation {#Sec11}
-----------------------------------------------------------------------------------------------------------

In order to identify the most critical period for CARV infection severity we analyzed characteristics and mortality rate according to the time of diagnosis for each one during the first 12 months of transplant. As shown in Fig. [1](#Fig1){ref-type="fig"}, most CARV episodes occurred within the first 6 months (227 out of 376, 60%), particularly in the 1st month after transplantation (63 out of 376, 28%). CARV LRTD was also more commonly observed within the first 6 months (83 out of 140, 59%). We likewise perceived that the 3-month all-cause mortality rate was clustered mainly in the first 6 months after transplant in the current series (25 out of 30 deaths, 83%). This was also observed when we analyzed different CARV types without statistically significant differences in mortality (see Table [2](#Tab2){ref-type="table"}). In fact, 8 out of 10 deaths with detected EvRh developed the respiratory virus infection within the first 6 months of transplant, as was also the case in 11 of 12 deaths with RSV, in all three cases with Influ, three out of five with PIV, all three cases with hMPV, both cases with HCoV, and in the only with ADV case. In light of these observations, we choose 6 months as the optimal cut-off time for comparison purposes.Fig. 1Characteristics of CARV infection episodes and mortality rate according to month of CARV detection after allo-HSCT. URTD upper respiratory tract disease, LRTD lower respiratory tract disease

Characteristics of CARV infection episodes according to the 6-month cut-off point {#Sec12}
---------------------------------------------------------------------------------

Patients' clinical and biological characteristics according to whether CARV infections developed earlier or later than 6 months after transplant are summarized in Table [3](#Tab3){ref-type="table"}. As expected, the group who developed CARV infections in the first 6 months had significantly higher incidence of severe immunosuppression-related factors. Use of HLA-mismatched donors and ISI score variables (lymphopenia, active GVHD, steroid therapy) were significantly overrepresented in the early CARV infection group (*p* ≤ 0.05 for all comparisons). CARV infection episodes in this group were more frequently accompanied by fever and/or hospitalization (*p* ≤ 0.03).Table 3Clinical and biological characteristics of respiratory virus infection episodes in allo-HSCT recipients according to timing of CARVCARV before d + 180 (*n* *=* 227)CARV after d + 180 (*n* *=* 149)*P* value*Transplant characteristics*ATG as part of conditioning56 (25)34 (23)0.4GVHD prophylaxis0.06 Sir-Tac15 (7)22 (15) CsA + MTX32 (14)24 (16) Post-Cy121 (53)71 (48) CsA + PDN and others59 (26)32 (22)HLA mismatch, *n* (%)116 (51)65 (44)0.09Type of donor, *n* (%)0.3 HLA-identical sibling donor64 (28)51 (34) Unrelated donor50 (22)40 (27) Umbilical cord blood50 (22)26 (17) Haplo-identical family donor63 (28)32 (21)*Immunodeficiency scoring index, n (%)*^a^ANC \< 0.5 × 10^9^/L (3 pts)46 (20)5 (3)0.001ALC \< 0.2 × 10^9^/L (3 pts)68 (30)12 (8)0.001Age ≥ 40 year (2 pts)150 (66)101 (68)0.4Myeloablative conditioning regimen (1 pt)133 (59)76 (51)0.09GvHD (acute or chronic; 1 pt)82 (36)87 (58)0.001Corticosteroids (1 pt)86 (38)51 (34)0.3Recent or preengraftment allo-HSCT (1 pt)64 (28)00.001ISI, *n* (%)0.001 Low risk (0--2)78 (34)57 (38) Moderate risk (3--6)96 (42)83 (56) High risk (7--12)53 (23)9 (6)*Other characteristics*^a^On IS, *n* (%)208 (92)104 (70)0.001ALC \< 0.1 × 10^9^/L, *n* (%)51 (22)4 (3)0.001ALC \< 0.5 × 10^9^/L, *n* (%)119 (52)25 (17)0.001*RVI characteristics and clinical consequences*CARV LRTD, *n* (%)87 (38)53 (36)0.3 Possible40 (46)32 (60) Proven47 (54)21 (40)Hospital admission, *n* (%)115 (51)40 (27)0.001Fever during CARV, *n* (%)148 (65)82 (55)0.03Day +90 overall mortality rate, *n* (%)25 (11)5 (3)0.005*CARV* community-acquired respiratory virus, *IFD* invasive pulmonary infectious fungal disease, *ATG* antithymocyte globuline, *GvHD* graft-versus-host disease, *Sir* sirolimus, *Tac* tacrolimus, *CsA* cyclosporine A, *MTX* methotrexate, *Post*-*Cy* post-transplant cyclophosphamide, *PDN* prednisone, *Allo*-*HSCT* allogeneic hematopoietic stem cell transplantation, *ANC* absolute neutrophil count, *ALC* absolute lymphocyte count, *IS* immunosuppressants, *LRTD* lower respiratory tract disease^a^All variables were captured at the time of CARV diagnosis

Analysis of risk factors for 3-month all-cause mortality {#Sec13}
--------------------------------------------------------

Logistic regression univariate and multivariate analyses of risk factors for 3-month all-cause mortality after CARV infection episodes and LRTD are shown in Table [4](#Tab4){ref-type="table"}.Table 4Univariate and multivariate analysis of risk factors for mortality after overall CARV infection and LRTDVariablesLog. regr. overall mortality (*n* = 376)Log. regr. overall mortality in recipients with LRTD CARV (*n* = 140)Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysisOR (95% C.I.).*P* valueOR (95% C.I.)*P* valueOR (95% C.I.).*P* valueOR (95% C.I.)*P* valueType of donor, *n* (%) HLA-identical sibling donor11 Alternative donor6.8 (1.58--29)0.01ns8.1 (1.1--63)0.044nsHLA mismatch4.8 (1.9--12.1)0.001ns5.5 (1.5--19.6)0.008nsATG as a part of conditioning4.9 (2.3--10.5)\<0.00012.8 (1.21--6.4)0.014.1 (1.6--10.8)0.0033.6 (1.2--10.6)0.019GVHD prophylaxisns Sir-Tac11 CsA + MTX6.7 (0.7--62)0.13.7 (0.5--62)0.3 Post-Cy3.2 (0.8--11.6)0.082.2 (0.7--13.6)0.09ns CsA + PDN and others0.5 (0.15--1.6)0.20.8 (0.45--2.6)0.2CARV LRTD5.3 (2.3--12.3)\<0.00013.4 (1.4--8.4)0.007NT No1 Proven4.6 (1.7--12.1)0.002NT Possible6.1 (2.3--15.6)0.001NTOn IS3.1 (0.7--13.1)0.131.4 (0.3--6.7)0.6ALC \< 0.5 × 109/L, *n* (%)3.6 (1.6--7.8)0.002NT2.4 (0.9--6.6)0.08nsALC \< 0.2 × 109/L^a^5 (2.33--10.8)\<0.00012.4 (1.03--5.6)0.042.9 (1.2--7.4)0.024NTALC \< 0.1 × 109/L2.3 (0.97--5.5)0.058NT1.2 (0.4--3.3)0.7NTANC \< 0.5 × 109/L^a^2.6 (1.07--6.1)0.034ns2.3 (0.8--6.3)0.11NTAge ≥ 40 years^a^0.99 (0.4--2.2)0.91.4 (0.5--4.2)0.5Active GvHD at time of RVI^a^1.4 (0.7--3)0.31.3 (0.5--3.1)0.6Periengraftment^a^2.3 (0.98--5.21)0.054ns1.5 (.6--4.2)0.4Allo-HSCT ≤ 6 months3.6 (1.33--9.5)0.013.04 (1.1--8.7)0.033.2 (1.1--10.3)0.0462.7 (1--15.1)0.05Myeloablative^a^3.8 (1.6--8.9)0.0022.7 (1.03--7.3)0.042NTCorticosteroids^a^3.33 (1.5--7.2)0.0023.9 (1.3--11.2)0.012NTAntiviral therapy0.6 (0.3--1.3)0.171.16 (0.46--2.9)0.7Type of RVI Mono infection11 Coinfection1.1 (0.4--2.7)0.90.9 (0.3--2.8)0.8ISINT Low risk (0--2)1 Moderate risk (3--6)6.24 (2.1--18.6)0.0014 (1.02--15.7)0.0472.8 (0.6--12)0.16 High risk (7--12)3.1 (1.3--7.1)0.0093.5 (1.3--9.9)0.0164 (1.3--10.6)0.017*C.I*. confidence interval, *Log*. *Regr* logistic regression model, *OR* odds ratio, *IFD* invasive pulmonary fungal disease, *ATG* antithymocyte globuline, *Sir* sirolimus, *Tac* tacrolimus, *CsA* cyclosporine A, *MTX* methotrexate, *Post*-*Cy* posttransplant cyclophosphamide, *PDN* prednisone, *CARV* *LRTD* community-acquired respiratory virus lower respiratory tract disease, *GvHD* graft-versus-host disease, *Allo*-*HSCT* allogeneic hematopoietic stem cell transplantation, *ISI* immunodeficiency score index, *ANC* absolute neutrophil count, *ALC* absolute lymphocyte count, *ns* not significant, *NT* not tested^a^These variables were included in the ISI score. When ISI score was not significant in the multivariate model; those with *p* value \< 0.1 in the univariate testing were finally included in the final multivariate model

We studied the 376 evaluable recipient/episode pairs to identify transplant and CARV conditions associated with mortality. Multivariate analysis identified four RFs: use of ATG as a part of conditioning regimen \[OR 2.8, 95% C.I. 1.21--6.4, *p* = 0.01\], CARV lower respiratory tract disease (OR 3.4, 95% C.I. 1.4--8.4, *p* = 0.007), CARV infection during the first 6 months of transplant (OR 3.04, 95% C.I. 1.1--8.7, *p* = 0.03), and absolute lymphocyte count \<0.2 × 10^9^/L (OR 2.4, 95% C.I. 1--5.3, *p* = 0.04).

We analyzed episodes of CARV involving LRTD to determine risk factors for mortality in these cases (*n* = 140). Multivariate analysis identified three independent factors associated with mortality. Again, ATG and early CARV infection (within the first 6 months) were associated with higher mortality (OR 3.6, 95% C.I. 1.2--10.6, *p* = 0.019 and OR 2.7, 95% C.I. 1--15.1, *p* = 0.05, respectively). Finally, high-risk ISI category was also associated with higher probability of mortality (OR 4, 95% C.I. 1.3--10.6, *p* = 0.017).

Developing CARV within the first 6 months of transplantation had a negative effect on OS at 3 months after CARV diagnosis. OS was 88% for early CARV infection episodes vs. 96% for those with late CARV infection (*p* = 0.009). OS was significantly lower in allo-HCT recipients with early CARV LRTD than in those with late CARV LRTD (78% vs. 92%, respectively, *p* = 0.04) (Fig. [2a, b](#Fig2){ref-type="fig"}).Fig. 2Overall survival according to development of **a** community acquired respiratory virus (CARV) respiratory virus infection (RVI) earlier or later than 6 months after transplant and **b** CARV lower respiratory tract disease (LRTD) earlier or later than 6 months after transplant

Timing of mortality and cause of death {#Sec14}
--------------------------------------

Fifteen recipients died by day 30 after CARV diagnosis. Six additional recipients died at day 60 whereas nine more recipients died by day 90 after CARV diagnosis. We did not observed significant differences among the cause of death according to the time of death after CARV detection. Eight and 22 recipients with URTD or LRTD died, respectively. Three, one and five and twelve, five and five recipients with URTD or LRTD died by day 30, 60, and 90, respectively. However, median time from CARV detection to death among recipients with URTD or LRTD was not statistically different (45 days vs. 37 days, *p* = 0.4, respectively).

Cause of death in recipients who die by day 30 were respiratory failure due to mono or coinfections (*n* = 10), including viral, bacterial and/or fungal coinfections, steroids-refractory GvHD (*n* = 3), posttransplant lymphoproliferative disease (*n* = 1) and baseline disease progression (*n* = 1). The additional six deaths occurring by day 60, were due to respiratory failure in the context of pulmonary mono or coinfections (*n* = 3), steroids-refractory GvHD (*n* = 2) and disease relapse (*n* = 1). For the remaining nine patients died by day 90 after CARV detection the causes of death were infectious respiratory failure (*n* = 4), steroids-refractory GvHD (*n* = 2), disease relapse (*n* = 2), and pulmonary malignancy (*n* = 1).

Discussion {#Sec15}
==========

This study shows that the timing of CARV infection during the first year of allo-HCT could be one of the major determinants of mortality, irrespective of CARV type. Our multivariate model showed that all-cause mortality at 3 months after CARV detection was significantly higher in recipients who developed CARV infection within the first 6 months of transplant. In addition, we found that ATG use as part of conditioning regimen, LRTD, and lymphopenia (\<0.2 × 10^9^/L) were also associated with higher risk of mortality. Risk factors for mortality among the CARV LRTD episodes included early CARV LRTD (within the first 6 months), ATG as a part of conditioning regimen, and high-risk ISI category.

Several studies have looked at the effect on mortality of when CARV infection occurs after allo-HCT using heterogeneous cut-off time points, showing discrepant results \[[@CR6], [@CR10], [@CR11], [@CR14]--[@CR24]\]. In fact, most of them were unable to find any association between timing and mortality \[[@CR14]--[@CR22], [@CR24]\]. In contrast, our detailed analysis of 3-month all-cause mortality conducted monthly during the first year revealed that most deaths occurred in recipients who developed a CARV infection within the first 6 months of transplant (see Fig. [1](#Fig1){ref-type="fig"}). We confirmed this observation in our multivariate model by including the "6 months" variable as an optimal cut-off time point in both overall and CARV LRTD. The differences observed between our study and others could be explained by two issues, the first being the risk of selection bias inherent to retrospective studies, with the inclusion of severe cases at any time after transplant. The power to detect differences in mortality according to the timing of CARV infection in severe cases is likely to be limited. Second, the most common cut-off time points used for comparison in prior reports were "day 0 to +30 vs. day +31 to +365 vs. \>day +365" and before or after day +100 of transplant. The selected intervals of both comparators overlap with our "6 month" cut-off. This may have distorted the effect of timing on mortality in prior studies. However, our findings suggest that the aforementioned cut-off time points are probably not optimal enough to differentiate the mortality risk. In fact, we explored these cut-off time points in our cohort, observing no statistical differences in terms of mortality. To our best knowledge, only one study, focused on paramyxovirus CARV infections, included a cut-off of 6 months in their analysis of mortality and found statistically significant differences \[[@CR11]\]. This is a predictable result since the 6-month cut-off corresponds to the anticipated length of immunosuppression in most allo-HCT recipients.

Given that the inclusion of several CARV types in the current study could be argued to confound our findings, we also independently analyzed the effect of timing in each of the CARVs across our entire cohort. We observed that the timing reported was consistent across all CARV types except HBoV (see Table [2](#Tab2){ref-type="table"}). Our pooled analysis with different CARVs can be justified by the fact that several prior studies comparing mortality and/or OS according to CARV type showed no significant differences \[[@CR23], [@CR24], [@CR31], [@CR32]\]. Our findings underscore the need for further prospective studies analyzing in detail the effect of timing of CARV infections on mortality in allo-HCT recipients; this elucidation could be of utmost importance for diagnostic purposes, infectious control measures, and to close monitoring of recipients who develop CARV infections within the first 6 months after transplant. In addition, if timing is confirmed as a major predictive factor for CARV severity, this will certainly raise further unanswered questions. Can the well-established clinical and/or biological risk factors and/or immunodeficiency scores reliably predict mortality due to later developing CARV after transplant? To the best of our knowledge, no studies have focused on mortality and risk factors related to CARV infections occurring beyond the first year of transplant.

Except for influenza virus and to some extend for RSV, currently there is an urgent need of new effective antiviral drugs against other CARV types. Although many molecules are under development \[[@CR33]\], in the meantime the efforts should be focused on having a timely microbiological diagnostic and preventing CARV transmission, in particular during the first 6 months after transplant. Medical education/information emphasizing what symptoms should be reported immediately to the transplant team, urgent clinical evaluation, and risk stratification within 24--48 h after the start of respiratory symptoms, rapid application of sensitive diagnostic test and prompt initiation of antiviral drugs in treatable CARV, as well as the early identification and treatment of direct and indirect CARV-related complications may be of value. In addition, there is also an urgent need in educating not only patients and healthcare givers about the risk of transmission associated with CARV infection but especially healthcare workers, managers, workplace health and safety and infection control staff, and administrators \[[@CR34]\].

Among the other variables associated with higher mortality in the current study, we confirm that LRTD and lymphopenia remain the most important and validated risk factors for mortality after CARV infection in the allo-HCT setting \[[@CR4]--[@CR7]\]. Besides these, use of ATG showed a direct association with mortality in both overall CARV and those limited to the LRTD. This finding is unsurprising, as ATG produces lymphopenia and a significant delay in T cell immune reconstitution that lasts longer than 1 year after stem cell infusion \[[@CR35], [@CR36]\]. Finally, we have corroborated the value of the high-risk ISI category in predicting mortality in LRTD caused by several CARV types. ISI was developed by investigators from the MD Anderson Cancer Center to predict outcome in allo-HCT recipients with RSV \[[@CR9]\]. This score demonstrated value in predicting LRTD progression \[[@CR1], [@CR10]\] and mortality \[[@CR10]\] in the context of influenza respiratory infection and RSV \[[@CR13]\]. However, the failure to differentiate risk of mortality between the moderate-risk and low-risk ISI category \[[@CR10], [@CR13]\] indicates room for improvement. In the meantime, the high-risk ISI category could be useful to assess the severity of several CARV types with LRTD involvement.

We acknowledge certain limitations of this study, such as the inclusion of several CARV types and the use of three different PCR methods differing (minimally) in analytical performance. Nonetheless, our study has strengths that merit consideration, notably the use of molecular testing and the prospective data collection with a CARV survey.

In conclusion, we provide evidence that the timing of CARV infection after allo-HCT could be of major interest due its considerable impact on outcome. Further prospective studies are warranted to confirm this finding.
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